113. 筋ジストロフィー [臨床試験数:567,薬物数:442(DrugBank:93),標的遺伝子数:55,標的パスウェイ数:151

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01580501
(ClinicalTrials.gov)
March 201217/4/2012PDE Inhibitors in DMD Study (Acute Dosing Study)Functional Muscle Ischemia and PDE5 Inhibition in Duchenne Muscular Dystrophy: Acute Dosing StudyDuchenne Muscular DystrophyDrug: Tadalafil and SildenafilCedars-Sinai Medical CenterNULLCompleted7 Years15 YearsMale12Phase 1United States
2NCT01350154
(ClinicalTrials.gov)
November 20114/5/2011Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy PatientsDoes Modulation of the nNOS System in Patients With Muscular Dystrophy and Defect nNOS Signalling Affect Cardiac, Muscular or Cognitive Function?Becker Muscular DystrophyDrug: Sildenafil;Drug: PlaceboRigshospitalet, DenmarkGlostrup University Hospital, CopenhagenCompleted18 Years80 YearsMale17Phase 2Denmark
3EUCTR2010-024659-10-DK
(EUCTR)
03/08/201121/06/2011Can certain muscle wasting diseases be improved with sildenafil?Can stimulation of the nNOS system in muscle disease with nNOS insufficiency improve heart and skeletal muscle function and cognition? Muscular dystrophy with nNOS insufficiency
MedDRA version: 14.0;Level: LLT;Classification code 10028301;Term: Muscle disorder NOS;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Revatio
Product Name: Sildenafil
Product Code: EMEA/H/C/000638
RigshospitaletNULLNot RecruitingFemale: no
Male: yes
Denmark
4NCT01359670
(ClinicalTrials.gov)
May 201123/5/2011Tadalafil and Sildenafil for Duchenne Muscular DystrophyFunctional Muscle Ischemia and PDE5A Inhibition in Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: Tadalafil;Drug: SildenafilCedars-Sinai Medical CenterParent Project Muscular DystrophyCompleted7 Years15 YearsMale30Early Phase 1United States
5NCT01168908
(ClinicalTrials.gov)
September 201022/7/2010Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular DystrophyPhase 2 Clinical Trial of Sildenafil for Cardiac Dysfunction in Duchenne Muscular Dystrophy and Becker Muscular DystrophyDuchenne Muscular Dystrophy;Becker Muscular DystrophyDrug: SildenafilHugo W. Moser Research Institute at Kennedy Krieger, Inc.Johns Hopkins UniversityTerminated18 Years50 YearsMale20Phase 2United States